Severe Acute Respiratory Syndrome

Severe acute respiratory syndrome (SARS) is a viral respiratory illness caused by a coronavirus, called SARS-associated coronavirus (SARS-CoV). SARS was first reported in Asia in February 2003. Over the next few months, the illness spread to more than two dozen countries in North America, South America, Europe, and Asia before the SARS global outbreak of 2003 was contained.

Severe Acute Respiratory Syndrome

SARS or Severe Acute Respiratory Syndrome is a viral respiratory illness caused by a coronavirus - the SARS associated coronavirus (SARS-CoV) - which can be life-threatening.

Overview

How SARS is Spread

Read More

SARS, Treatment, Control and Tests

Read More

SARS: Tips for Travellers

Read More

Latest Severe Acute Respiratory Syndrome News and Research

Azvudine beats paxlovid in reducing COVID-19 deaths

Azvudine beats paxlovid in reducing COVID-19 deaths

In hospitalized COVID-19 patients, azvudine shows lower all-cause mortality and fewer adverse events than Paxlovid, with added antitumor effects observed.

21 Jan 2025

Tofacitinib reduces SARS-CoV-2 infection risk in patients with PTPN2 deficiency

Tofacitinib reduces SARS-CoV-2 infection risk in patients with PTPN2 deficiency

Researchers report the ability of tofacitinib to reduce infection risk with SARS-CoV-2 in individuals who are deficient in PTPN2.

17 Jan 2025

COVID-19 dramatically raises the risk of developing ME/CFS

COVID-19 dramatically raises the risk of developing ME/CFS

Study highlights a fourfold increase in ME/CFS risk among COVID-19 patients, with 89% of post-COVID ME/CFS cases overlapping with severe long COVID symptom clusters.

16 Jan 2025

Extended Paxlovid courses show mixed results for long COVID symptoms

Extended Paxlovid courses show mixed results for long COVID symptoms

A study indicates that longer Paxlovid treatments could improve long COVID symptoms in some patients, highlighting the need for tailored antiviral strategies.

8 Jan 2025

Hidden culprit: Human metapneumovirus identified in severe adult pneumonia case

Hidden culprit: Human metapneumovirus identified in severe adult pneumonia case

Severe pneumonia caused by human metapneumovirus in an immunocompetent adult highlights diagnostic challenges and underscores the need for rapid molecular diagnostics to improve outcomes.

6 Jan 2025

Breakthrough in immunology: AbMAP’s novel approach to antibody modeling

Breakthrough in immunology: AbMAP’s novel approach to antibody modeling

Researchers developed AbMAP, a cutting-edge framework leveraging transfer learning to model antibody hypervariable regions, significantly improving design and immune repertoire analysis.

2 Jan 2025

Scientists pinpoint regions and species fueling coronavirus evolution in bats

Scientists pinpoint regions and species fueling coronavirus evolution in bats

Study uncovers the evolution, transmission, and geographic spread of bat coronaviruses in China, revealing key insights into hotspots and the origins of SARS-CoV-2.

1 Jan 2025

Breastfeeding after COVID-19 vaccination is safe, with minimal changes to milk composition

Breastfeeding after COVID-19 vaccination is safe, with minimal changes to milk composition

This study reveals how SARS-CoV-2 infection significantly alters human milk composition, while COVID-19 vaccination causes minimal, transient changes, underscoring the safety of breastfeeding during vaccination.

19 Dec 2024

Breakthrough in antigen recognition: TRACeR-I enhances immune targeting

Breakthrough in antigen recognition: TRACeR-I enhances immune targeting

Researchers describe TRACeR-I, a protein platform that can be used to engineer immune responses.

19 Dec 2024

New long COVID index highlights five symptom subtypes

New long COVID index highlights five symptom subtypes

Researchers provide a detailed report of the updated 2024 long COVID research index.

19 Dec 2024

Long COVID affects 8.4% of U.S. adults, with income and geography shaping impact

Long COVID affects 8.4% of U.S. adults, with income and geography shaping impact

Long COVID affects 8.4% of U.S. adults, with significant disparities based on sex, income, and geography, limiting daily activities for many.

17 Dec 2024

Gut microbiome during acute infection predicts risk of long COVID

Gut microbiome during acute infection predicts risk of long COVID

The study identifies gut microbiome signatures during acute SARS-CoV-2 infection as predictors of long COVID, enhancing understanding of symptom variability.

16 Dec 2024

Researchers classify post-COVID subtypes and uncover vaccination’s protective role

Researchers classify post-COVID subtypes and uncover vaccination’s protective role

Researchers identify four distinct post-COVID subtypes, reveal key risk factors, and emphasize the protective role of vaccination in mitigating long-term impacts.

12 Dec 2024

Long-COVID lingers in children

Long-COVID lingers in children

A 24-month study reveals that 7.2% of children consistently experience long-COVID symptoms, with tiredness, sleep issues, and headaches most commonly reported, highlighting the need for targeted interventions.

5 Dec 2024

SARS-CoV-2 spike protein found lingering in brain regions

SARS-CoV-2 spike protein found lingering in brain regions

Researchers find that SARS-CoV-2 spike protein persists in the skull-meninges-brain axis, driving neuroinflammation, neurodegeneration, and heightened vulnerability to brain injuries.

3 Dec 2024

Reinstating masking curbs hospital viral outbreaks, study confirms

Reinstating masking curbs hospital viral outbreaks, study confirms

Researchers investigate how changes in hospital policies for SARS-CoV-2 testing and masking have influenced hospital-acquired respiratory viral infections.

1 Dec 2024

Boosters cut long COVID risk significantly

Boosters cut long COVID risk significantly

Vaccination, especially booster doses, reduces the risk of long COVID by up to 29%, highlighting its critical role in preventing lingering Omicron-era complications.

25 Nov 2024

SARS-CoV-2 hijacks cholesterol trafficking to fuel infection and evade immune responses

SARS-CoV-2 hijacks cholesterol trafficking to fuel infection and evade immune responses

SARS-CoV-2 disrupts cholesterol metabolism by using its ORF3a protein to sequester cholesterol in lysosomes, reducing BMP levels and optimizing viral survival. This novel mechanism offers insights into long-term metabolic complications of COVID-19.

19 Nov 2024

Phase 2 study evaluates safety and efficacy of asunercept in COVID-19 patients

Phase 2 study evaluates safety and efficacy of asunercept in COVID-19 patients

The ASUNCTIS trial evaluated asunercept's safety and efficacy in COVID-19, showing trends toward faster recovery despite not meeting statistical significance.

18 Nov 2024

Futuristic AI-powered virtual lab designs potent SARS-CoV-2 nanobodies

Futuristic AI-powered virtual lab designs potent SARS-CoV-2 nanobodies

AI-human collaboration in a "Virtual Lab" successfully designs and experimentally validates nanobodies with enhanced binding to SARS-CoV-2 variants, offering a novel approach to interdisciplinary research.

14 Nov 2024

1
2
3
4
...
518
Next

Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net.

To start a conversation, please log into your AZoProfile account first, or create a new account.

Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content.

A few things you need to know before we start. Please read and accept to continue.

Use of “Azthena” is subject to the terms and conditions of use as set out by OpenAI.
Content provided on any AZoNetwork sites are subject to the site Terms & Conditions and Privacy Policy.
Large Language Models can make mistakes. Consider checking important information.

I understand, and agree to receive occasional emails about Azthena such as usage tips and new feature announcements.

Please check the box above to proceed.

Great. Ask your question.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.